References
- King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414–31
- Poskiparta M, Kasila K, Kiuru P. Dietary and physical activity counselling on type 2 diabetes and impaired glucose tolerance by physicians and nurses in primary healthcare in Finland. Scand J Prim Health Care 2006; 24: 206–10
- Klimt CR, Knatterud GL, Meinert CL, Prout TE, (UGDP). A study of the effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 1970; 19: 747–830
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;12:837–53.
- Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758–67
- Wandell PE. Quality of life of patients with diabetes mellitus: An overview of research in primary health care in the Nordic countries. Scand J Prim Health Care 2005; 23: 68–74
- Yki-Järvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 1426–33
- Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with non-insulin-dependent diabetes mellitus. Diabetologia 1999; 42: 406–12
- DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397–405.
- Gaude P, Vedel P, Larsen N, Jensen GVH, Parving H, Pedersen O. Multifactorial interventions and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–93
- Qiao Q, Tuomilehto J, Borch-Johnsen K. Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia 2003; 46(Suppl 1)17–21
- Ceriello A. Postprandial hyperglycaemia and diabetes complications: Is it time to treat?. Diabetes 2005; 54: 1–7
- Madsbad S, Krarup T, McNair P, Christiansen C, Faber OK, Transbol I, Binder C. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand 1981; 210: 153–6
- Diabetes mellitus. Report of a WHO Study Group. World Health Organization Technical Report Series 727. Geneva: World Health Organization; 1985.
- Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758–67
- Yki-Järvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkilä M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: A randomized, controlled trial. Ann Intern Med 1999; 130: 389–96
- Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881–5
- Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080–6.
- Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, Vähätalo M, Virtamo H, Nikkilä K, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study. Diabetologia 2006; 49: 442–51
- Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269–74